<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00395512</url>
  </required_header>
  <id_info>
    <org_study_id>01-06-TL-322OPI-002</org_study_id>
    <secondary_id>2006-005492-17</secondary_id>
    <secondary_id>U1111-1113-8616</secondary_id>
    <nct_id>NCT00395512</nct_id>
  </id_info>
  <brief_title>Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and
      pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with
      diet and exercise alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are approximately 19 million people in the United States who have been diagnosed with
      diabetes mellitus, of which 90% to 95% is type 2. The prevalence of type 2 diabetes varies
      among racial and ethnic populations and has been shown to correlate with age, obesity, family
      history, history of gestational diabetes, and physical inactivity. Over the next decade, a
      marked increase in the number of adults with diabetes mellitus is expected, placing an
      ever-increasing burden on families and the health care system.

      Current pharmacologic interventions for type 2 diabetes mellitus include a diverse range of
      antidiabetic medications with different mechanisms of action including insulin and insulin
      analogues, sulfonylureas, metformin, meglitinides, thiazolidinediones, inhibitors of alpha-
      glucosidase, analogs of glucagon-like peptide-1, and synthetic analogues of human amylin.
      Despite the variety of medications, many have clinically important or potentially
      life-threatening side effects, restricted use in many subpopulations, concerns with long-term
      tolerability, and challenges related to compliance due to side effects and route of
      administration. All of these reasons contribute to the difficulties patients have reaching
      the target glycosylated hemoglobin level less than 7%.

      SYR-322 (alogliptin) is a selective, orally available inhibitor of the dipeptidyl peptidase-4
      enzyme. Dipeptidyl peptidase-4 enzyme is thought to be primarily responsible for the in vivo
      degradation of 2 peptide hormones released in response to nutrient ingestion, namely
      glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. Both peptides exert
      important effects on islet beta cells to stimulate glucose-dependent insulin secretion as
      well as regulating beta cell proliferation and cytoprotection. Glucagon-like peptide-1, but
      not glucose-dependent insulinotropic peptide, inhibits gastric emptying, glucagon secretion,
      and food intake. Glucose-dependent insulinotropic peptide has been shown to enhance insulin
      secretion by direct interaction with a glucose-dependent insulinotropic peptide -specific
      receptor on islet beta cells. The glucose-lowering actions of glucagon-like peptide-1, but
      not glucose-dependent insulinotropic peptide, are preserved in patients with type 2 diabetes
      mellitus.

      Pioglitazone (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd.
      (Osaka, Japan) that is approved for the treatment of type 2 diabetes mellitus. Pioglitazone
      is a selective peroxisome proliferator-activated receptor-gamma agonist that decreases
      insulin resistance in the periphery and liver resulting in increased insulin-dependent
      glucose disposal and decreased hepatic glucose output.

      As the rate of newly diagnosed cases of type 2 diabetes mellitus continues to grow, so does
      the need for products that will provide better glycemic control and improved safety and
      tolerability. Alogliptin and pioglitazone have complementary actions. Alogliptin inhibits the
      degradation of glucagon-like peptide-1 by inhibiting the enzyme dipeptidyl peptidase IV, thus
      augmenting glucose-dependent insulin secretion while pioglitazone is a peripheral and hepatic
      insulin sensitizer. Given the complementary mechanisms of action of alogliptin (stimulates
      insulin secretion) and pioglitazone (enhances insulin sensitivity), the addition of
      combination therapy in treatment naïve type 2 diabetes patients may potentially allow the
      patients to reach and maintain their glycosylated hemoglobin goal more effectively.

      The aim of this study is to evaluate the effectiveness of the combination of alogliptin with
      pioglitazone in patients who are inadequately controlled on diet and exercise alone. Study
      participation is anticipated to be approximately 8.5 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16 and 20.</time_frame>
    <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose Over Time</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Marked Hyperglycemia</measure>
    <time_frame>Weeks 1, 2, 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Rescue Criteria</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory:
After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L);
From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L);
From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Proinsulin</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proinsulin/Insulin Ratio</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-peptide Levels</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements:
HOMA IR = fasting plasma insulin (µIU/mL) * fasting plasma glucose (mmol/L) / 22.5
A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostatic Model Assessment Beta Cell Function</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population.
HOMA %B = 20 * insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5
The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight</measure>
    <time_frame>Baseline and Weeks 8, 12, 20 and 26.</time_frame>
    <description>Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol Level</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low-Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-Density Lipoprotein Cholesterol</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglyceride Levels</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
    <description>Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Free Fatty Acids</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasminogen Activator Inhibitor-1</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High-sensitivity C-Reactive Protein</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A1</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein A2</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein B</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Apolipoprotein C-III</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VLDL / Chylomicron Triglycerides</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in VLDL Particles</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean VLDL Particle Size</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Low Density Lipoprotein (LDL) Particles</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean LDL Particle Size</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein (HDL) Particles</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean HDL Particle Size</measure>
    <time_frame>Baseline and Weeks 12 and 26.</time_frame>
    <description>Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">655</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 25 mg QD+ Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin tablets.</description>
    <arm_group_label>Alogliptin 25 mg QD</arm_group_label>
    <arm_group_label>Alogliptin 25 mg QD+ Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_label>Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD</arm_group_label>
    <other_name>SYR-322</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone tablets.</description>
    <arm_group_label>Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_label>Alogliptin 25 mg QD+ Pioglitazone 30 mg QD</arm_group_label>
    <arm_group_label>Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD</arm_group_label>
    <other_name>Actos</other_name>
    <other_name>AD4833</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets.</description>
    <arm_group_label>Alogliptin 25 mg QD</arm_group_label>
    <arm_group_label>Pioglitazone 30 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Historical diagnosis of type 2 diabetes.

          -  Failed treatment with diet and exercise for at least 2 months prior to Screening.

          -  Is experiencing inadequate glycemic control as defined as glycosylated hemoglobin
             concentration between 7.5-11%, inclusive.

          -  Has received any antidiabetic therapy for less than 7 days within 3 months prior to
             Screening.

          -  Has a body mass index greater than or equal to 23 kg/m2 and less than or equal to45
             kg/m2.

          -  Fasting C-peptide greater than or equal to 0.8 ng per mL.

          -  Regular use of other, non-excluded medications is allowed if participant is on a
             stable dose for at least 4 weeks prior to Screening.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

          -  Must be willing and able to monitor their blood concentrations with a home glucose
             monitor.

        Exclusion Criteria

          -  Systolic blood pressure greater than or equal to 160 mmHg and diastolic blood pressure
             greater than or equal to 100 mmHg.

          -  Hemoglobin less than or equal to 12 g per dL for males and less than or equal to 10 g
             per dL for females.

          -  Alanine aminotransferase greater than or equal to 2.5times the upper limit of normal.

          -  Serum creatinine greater than 2.0 mg per dL.

          -  Thyroid stimulating hormone level greater than the upper limit of normal range.

          -  Major illness or debility that in the investigator's opinion prohibits the subject
             from completing the study.

          -  Urine albumin to creatinine ratio of greater than 1000 ug per mg at Screening. If
             elevated, the subject may be rescreened within 1 week.

          -  History of cancer, other than squamous cell or basal cell carcinoma of the skin, that
             has not been in full remission for at least 5 years prior to Screening

          -  History of laser treatment for proliferative diabetic retinopathy within 6 months
             prior to Screening.

          -  History of gastroparesis.

          -  Has New York Heart Association Class I to IV heart failure regardless of therapy.

          -  History of coronary angioplasty, coronary stent placement, coronary bypass surgery, or
             myocardial infarction within 6 months prior to Screening.

          -  History of any hemoglobinopathy that may affect determination of glycosylated
             hemoglobin.

          -  History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus.

          -  History of a psychiatric disorder that will affect participant's ability to
             participate in the study.

          -  History of angioedema in association with use of angiotensin-converting enzyme
             inhibitors or angiotensin-II receptor inhibitors.

          -  Any alteration in angiotensin-II receptor inhibitors within 2 months prior to
             Randomization, if applicable.

          -  History of alcohol (defined as regular or daily consumption of more than 4 alcoholic
             drinks per day) or substance abuse (defined as illicit drug use) within 2 years prior
             to Screening.

          -  Received any investigational drug within 30 days prior to Screening or a history of
             receipt of an investigational antidiabetic drug within 3 months prior to Screening.

          -  Previously participated in an investigational study of SYR-322.

          -  Glycosylated hemoglobin concentration between 7.5-11%, inclusive, and a fasting plasma
             glucose less than 310 mg per dL.

          -  At least 75% compliant with the single-blind placebo regimen during the
             run-in/stabilization period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VP, Biological Sciences</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Columbiana</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hueytown</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northport</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Foothill Ranch</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sebastian</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnesville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prince Frederick</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benzonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portage</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Clair Shores</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cicero</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northeast</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Havertown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northern Cambria</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Conroe</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Euless</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seguin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugarland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewisburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cap. Fed.</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chacabuco</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morón</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiás</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belém</city>
        <state>PA</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maringá</city>
        <state>RP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marília</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mogi das Cruzes</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slavonski Brod</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mako</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaffa Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kedainiai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gniewkowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kamieniec Zabkowicki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leczyca</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Interna klinika II</city>
        <state>Nitra</state>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bysterica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sahy</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>Kwa-Zulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Lynne</city>
        <state>Pretoria</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellville</city>
        <state>Western Province</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Province</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
    <country>Peru</country>
  </removed_countries>
  <link>
    <url>http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&amp;fileTypeCode=ACTOSPI</url>
    <description>ACTOS® Package Insert</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <results_reference>
    <citation>Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care. 2010 Nov;33(11):2406-8. doi: 10.2337/dc10-0159. Epub 2010 Aug 19.</citation>
    <PMID>20724648</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2006</study_first_submitted>
  <study_first_submitted_qc>November 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2006</study_first_posted>
  <results_first_submitted>February 19, 2013</results_first_submitted>
  <results_first_submitted_qc>February 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2013</results_first_posted>
  <disposition_first_submitted>July 30, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>July 30, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism Disorder</keyword>
  <keyword>Dysmetabolic Syndrome</keyword>
  <keyword>Type II Diabetes</keyword>
  <keyword>Diabetes Mellitus, Lipoatrophic</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 268 investigative sites in 23 countries from 02 November 2006 to 13 February 2008.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of type 2 diabetes who were inadequately controlled with diet and exercise were randomized to 1 of 4 treatment groups in a 1:1:1:1 ratio as follows: Alogliptin alone, pioglitazone alone, alogliptin 25 mg + pioglitazone 30 mg and alogliptin 12.5 mg + pioglitazone 30 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Alogliptin 25 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Pioglitazone 30 mg</title>
          <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="164"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="163"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="163">1 participant was lost to follow-up post visit 1. It is unknown if they took any study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="136"/>
                <participants group_id="P4" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hyperglycemic Rescue</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alogliptin 25 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pioglitazone 30 mg</title>
          <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="163"/>
            <count group_id="B3" value="164"/>
            <count group_id="B4" value="164"/>
            <count group_id="B5" value="655"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="10.38"/>
                    <measurement group_id="B2" value="51.5" spread="10.72"/>
                    <measurement group_id="B3" value="52.8" spread="11.01"/>
                    <measurement group_id="B4" value="53.5" spread="11.37"/>
                    <measurement group_id="B5" value="52.6" spread="10.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="140"/>
                    <measurement group_id="B4" value="130"/>
                    <measurement group_id="B5" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.72" spread="19.033"/>
                    <measurement group_id="B2" value="85.53" spread="16.254"/>
                    <measurement group_id="B3" value="85.39" spread="20.374"/>
                    <measurement group_id="B4" value="84.38" spread="20.378"/>
                    <measurement group_id="B5" value="85.50" spread="19.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.61" spread="5.587"/>
                    <measurement group_id="B2" value="30.87" spread="4.938"/>
                    <measurement group_id="B3" value="31.32" spread="5.354"/>
                    <measurement group_id="B4" value="30.71" spread="5.621"/>
                    <measurement group_id="B5" value="31.13" spread="5.382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.23" spread="3.559"/>
                    <measurement group_id="B2" value="3.20" spread="3.739"/>
                    <measurement group_id="B3" value="3.05" spread="3.328"/>
                    <measurement group_id="B4" value="3.36" spread="4.166"/>
                    <measurement group_id="B5" value="3.21" spread="3.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)</title>
        <description>The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>The Full analysis Set (all randomized patients who took at least 1 dose of double-blind study drug) where a Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)</title>
          <description>The change from Baseline to Week 26 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound).</description>
          <population>The Full analysis Set (all randomized patients who took at least 1 dose of double-blind study drug) where a Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.081"/>
                    <measurement group_id="O2" value="-1.15" spread="0.083"/>
                    <measurement group_id="O3" value="-1.71" spread="0.081"/>
                    <measurement group_id="O4" value="-1.56" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy variable was defined as change from Baseline in HbA1c level at Week 26. The null hypothesis was that the average change from Baseline in HbA1c at Week 26 for the A25 + P30 group would be equal to the average changes for the P30 alone and A25 alone groups; further, under the null hypothesis, the average change from Baseline in HbA1c at Week 26 for the A12.5 + P30 group was equal to the average change for the P30 alone group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c Over Time</title>
        <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16 and 20.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c Over Time</title>
          <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at 4 week intervals during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=145, 146, 144, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.043"/>
                    <measurement group_id="O2" value="-0.30" spread="0.043"/>
                    <measurement group_id="O3" value="-0.62" spread="0.043"/>
                    <measurement group_id="O4" value="-0.51" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=160, 153, 158, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.058"/>
                    <measurement group_id="O2" value="-0.72" spread="0.060"/>
                    <measurement group_id="O3" value="-1.19" spread="0.059"/>
                    <measurement group_id="O4" value="-1.03" spread="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=160, 153, 158, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.070"/>
                    <measurement group_id="O2" value="-1.04" spread="0.071"/>
                    <measurement group_id="O3" value="-1.57" spread="0.070"/>
                    <measurement group_id="O4" value="-1.34" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160, 153, 158, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="0.080"/>
                    <measurement group_id="O2" value="-1.17" spread="0.082"/>
                    <measurement group_id="O3" value="-1.67" spread="0.081"/>
                    <measurement group_id="O4" value="-1.43" spread="0.081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=160, 153, 158, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.077"/>
                    <measurement group_id="O2" value="-1.20" spread="0.079"/>
                    <measurement group_id="O3" value="-1.72" spread="0.078"/>
                    <measurement group_id="O4" value="-1.54" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline at Week 20 between Pioglitazone 30 mg and Alogliptin 12.5 mg + Pioglitazone 30 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline at Week 20 between Pioglitazone 30 mg and Alogliptin 25 mg + Pioglitazone 30 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline at Week 20 between Alogliptin 25 mg and Alogliptin 25 mg + Pioglitazone 30 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and geographic region as class variables and baseline HbA1c as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose Over Time</title>
        <description>The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose Over Time</title>
          <description>The change from Baseline in fasting plasma glucose was assessed at weeks 1, 2, 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline plasma glucose as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=148, 146, 152, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" spread="2.93"/>
                    <measurement group_id="O2" value="-7.3" spread="2.95"/>
                    <measurement group_id="O3" value="-26.6" spread="2.90"/>
                    <measurement group_id="O4" value="-23.3" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=161, 156, 162, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="2.87"/>
                    <measurement group_id="O2" value="-14.2" spread="2.92"/>
                    <measurement group_id="O3" value="-33.5" spread="2.87"/>
                    <measurement group_id="O4" value="-30.9" spread="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=162, 157, 162, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="2.72"/>
                    <measurement group_id="O2" value="-31.9" spread="2.76"/>
                    <measurement group_id="O3" value="-41.4" spread="2.72"/>
                    <measurement group_id="O4" value="-39.7" spread="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=162, 157, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="2.80"/>
                    <measurement group_id="O2" value="-38.0" spread="2.84"/>
                    <measurement group_id="O3" value="-50.4" spread="2.80"/>
                    <measurement group_id="O4" value="-48.4" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=162, 157, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.5" spread="3.01"/>
                    <measurement group_id="O2" value="-42.4" spread="3.05"/>
                    <measurement group_id="O3" value="-51.9" spread="3.01"/>
                    <measurement group_id="O4" value="-49.3" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=162, 157, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.9" spread="3.11"/>
                    <measurement group_id="O2" value="-40.6" spread="3.16"/>
                    <measurement group_id="O3" value="-52.7" spread="3.12"/>
                    <measurement group_id="O4" value="-46.6" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=162, 157, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" spread="3.06"/>
                    <measurement group_id="O2" value="-42.0" spread="3.11"/>
                    <measurement group_id="O3" value="-54.0" spread="3.07"/>
                    <measurement group_id="O4" value="-47.5" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=162, 157, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" spread="3.26"/>
                    <measurement group_id="O2" value="-37.3" spread="3.31"/>
                    <measurement group_id="O3" value="-50.2" spread="3.27"/>
                    <measurement group_id="O4" value="-48.5" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline in fasting plasma glucose at Week 26 between Pioglitazone 30 mg and Alogliptin 12.5 mg + Pioglitazone 30 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from an ANCOVA model with treatment and geographic region as class variables and Baseline fasting plasma glucose as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.3</ci_lower_limit>
            <ci_upper_limit>-2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline in fasting plasma glucose at Week 26 between Pioglitazone 30 mg and Alogliptin 25 mg + Pioglitazone 30 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from an ANCOVA model with treatment and geographic region as class variables and Baseline fasting plasma glucose as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-12.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.0</ci_lower_limit>
            <ci_upper_limit>-3.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline in fasting plasma glucose at Week 26 between Alogliptin 25 mg and Alogliptin 25 mg + Pioglitazone 30 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>P-value is from an ANCOVA model with treatment and geographic region as class variables and Baseline fasting plasma glucose as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-24.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.5</ci_lower_limit>
            <ci_upper_limit>-15.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Marked Hyperglycemia</title>
        <description>Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.</description>
        <time_frame>Weeks 1, 2, 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>Full analysis set including patients with at least one non-missing fasting plasma glucose result in the specified interval in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Marked Hyperglycemia</title>
          <description>Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL. Study week windows are defined to place hyperglycemia into visit categories.</description>
          <population>Full analysis set including patients with at least one non-missing fasting plasma glucose result in the specified interval in each treatment group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 to &lt; Week 4 (n=162, 157, 162, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5"/>
                    <measurement group_id="O2" value="31.8"/>
                    <measurement group_id="O3" value="18.5"/>
                    <measurement group_id="O4" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 to &lt; Week 8 (n=153, 147, 148, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="15.0"/>
                    <measurement group_id="O3" value="10.8"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 to &lt; Week 12 (n=151, 146, 152, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2"/>
                    <measurement group_id="O2" value="11.6"/>
                    <measurement group_id="O3" value="7.2"/>
                    <measurement group_id="O4" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 to &lt; Week 16 (n=153, 141, 148, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="9.2"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 to &lt; Week 20 (n=142, 135, 144, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 to Week 26 (n=130, 132, 143, 128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="10.5"/>
                    <measurement group_id="O4" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=162, 157, 162, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="38.2"/>
                    <measurement group_id="O3" value="25.3"/>
                    <measurement group_id="O4" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Rescue Criteria</title>
        <description>Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory:
After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L);
From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L);
From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.</description>
        <time_frame>Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>Full analysis set including patients with visits during or after the specified interval in each treatment group.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Rescue Criteria</title>
          <description>Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 5 days after the first sample and analyzed by the central laboratory:
After more than 4 weeks of treatment but prior to the Week 8 Visit: a single fasting plasma glucose ≥310 mg/dL (≥17.5 mmol/L);
From the Week 8 Visit but prior to the Week 12 Visit: a single fasting plasma glucose ≥275 mg/dL (≥15.27 mmol/L);
From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% and ≤0.5% reduction in HbA1c as compared with the Baseline HbA1c.</description>
          <population>Full analysis set including patients with visits during or after the specified interval in each treatment group.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 to &lt; Week 8 (n=160, 156, 161, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 to &lt; Week 12 (n=158, 151, 157, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 to &lt; Week 16 (n=156, 145, 153, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 to &lt; Week 20 (n=150, 138, 149, 134)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="2.2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 to Week 26 (n=132, 133, 146, 130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall (n=160, 156, 161, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.</description>
        <time_frame>Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤6.5%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="16.6"/>
                    <measurement group_id="O3" value="27.4"/>
                    <measurement group_id="O4" value="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.</description>
        <time_frame>Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4"/>
                    <measurement group_id="O2" value="33.7"/>
                    <measurement group_id="O3" value="62.8"/>
                    <measurement group_id="O4" value="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.</description>
        <time_frame>Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.5%</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with HbA1c ≤ 7.5%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="72.0"/>
                    <measurement group_id="O4" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 0.5%</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 0.5%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5"/>
                    <measurement group_id="O2" value="70.6"/>
                    <measurement group_id="O3" value="89.6"/>
                    <measurement group_id="O4" value="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.0%</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3"/>
                    <measurement group_id="O2" value="54.6"/>
                    <measurement group_id="O3" value="75.6"/>
                    <measurement group_id="O4" value="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 1.5%.</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 1.5%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="33.1"/>
                    <measurement group_id="O3" value="57.3"/>
                    <measurement group_id="O4" value="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%</title>
        <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Decrease in Glycosylated Hemoglobin Greater Than or Equal to 2.0%</title>
          <description>Clinical response at Week 26 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of ≥ 2.0%.</description>
          <population>Full Analysis Set. Participants who did not complete the scheduled Week 26 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.7"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="34.1"/>
                    <measurement group_id="O4" value="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Proinsulin</title>
        <description>Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Proinsulin</title>
          <description>Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline proinsulin as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>pmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=136, 134, 135, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="1.74"/>
                    <measurement group_id="O2" value="-12.1" spread="1.75"/>
                    <measurement group_id="O3" value="-16.0" spread="1.74"/>
                    <measurement group_id="O4" value="-12.3" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=150, 143, 146, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="1.57"/>
                    <measurement group_id="O2" value="-14.9" spread="1.60"/>
                    <measurement group_id="O3" value="-18.2" spread="1.59"/>
                    <measurement group_id="O4" value="-17.7" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=150, 143, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="1.48"/>
                    <measurement group_id="O2" value="-16.0" spread="1.52"/>
                    <measurement group_id="O3" value="-18.6" spread="1.50"/>
                    <measurement group_id="O4" value="-16.7" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=150, 143, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.88"/>
                    <measurement group_id="O2" value="-16.3" spread="1.93"/>
                    <measurement group_id="O3" value="-16.0" spread="1.90"/>
                    <measurement group_id="O4" value="-13.1" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=150, 143, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="1.75"/>
                    <measurement group_id="O2" value="-16.1" spread="1.79"/>
                    <measurement group_id="O3" value="-19.8" spread="1.76"/>
                    <measurement group_id="O4" value="-15.5" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=150, 143, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="1.64"/>
                    <measurement group_id="O2" value="-13.2" spread="1.68"/>
                    <measurement group_id="O3" value="-18.3" spread="1.66"/>
                    <measurement group_id="O4" value="-15.1" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin</title>
        <description>The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin</title>
          <description>The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least Squares Means were from an ANCOVA model with treatment and geographic region as class variables and baseline insulin as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>μIU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=135, 133, 133, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.684"/>
                    <measurement group_id="O2" value="-4.74" spread="0.689"/>
                    <measurement group_id="O3" value="-4.67" spread="0.687"/>
                    <measurement group_id="O4" value="-4.27" spread="0.659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=150, 142, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.811"/>
                    <measurement group_id="O2" value="-4.41" spread="0.834"/>
                    <measurement group_id="O3" value="-4.75" spread="0.818"/>
                    <measurement group_id="O4" value="-4.86" spread="0.797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=150, 142, 148, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.883"/>
                    <measurement group_id="O2" value="-4.08" spread="0.907"/>
                    <measurement group_id="O3" value="-2.98" spread="0.887"/>
                    <measurement group_id="O4" value="-4.65" spread="0.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=150, 142, 148, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.829"/>
                    <measurement group_id="O2" value="-4.49" spread="0.852"/>
                    <measurement group_id="O3" value="-3.65" spread="0.833"/>
                    <measurement group_id="O4" value="-2.73" spread="0.814"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=150, 142, 148, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.844"/>
                    <measurement group_id="O2" value="-4.56" spread="0.868"/>
                    <measurement group_id="O3" value="-4.61" spread="0.848"/>
                    <measurement group_id="O4" value="-3.06" spread="0.829"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=150, 142, 148, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.755"/>
                    <measurement group_id="O2" value="-4.06" spread="0.776"/>
                    <measurement group_id="O3" value="-3.86" spread="0.759"/>
                    <measurement group_id="O4" value="-3.72" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proinsulin/Insulin Ratio</title>
        <description>The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proinsulin/Insulin Ratio</title>
          <description>The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20 and 26 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment and geographic region as class variables and Baseline proinsulin/insulin ratio as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=135, 133, 133, 145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.073" spread="0.0150"/>
                    <measurement group_id="O2" value="-0.047" spread="0.0151"/>
                    <measurement group_id="O3" value="-0.080" spread="0.0151"/>
                    <measurement group_id="O4" value="-0.056" spread="0.0144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=149, 142, 146, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.041" spread="0.0140"/>
                    <measurement group_id="O2" value="-0.085" spread="0.0144"/>
                    <measurement group_id="O3" value="-0.094" spread="0.0142"/>
                    <measurement group_id="O4" value="-0.102" spread="0.0138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=149, 142, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.062" spread="0.0122"/>
                    <measurement group_id="O2" value="-0.098" spread="0.0125"/>
                    <measurement group_id="O3" value="-0.123" spread="0.0123"/>
                    <measurement group_id="O4" value="-0.095" spread="0.0120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=149, 142, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.0173"/>
                    <measurement group_id="O2" value="-0.081" spread="0.0177"/>
                    <measurement group_id="O3" value="-0.115" spread="0.0174"/>
                    <measurement group_id="O4" value="-0.090" spread="0.0170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=149, 142, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.057" spread="0.0173"/>
                    <measurement group_id="O2" value="-0.076" spread="0.0177"/>
                    <measurement group_id="O3" value="-0.124" spread="0.0174"/>
                    <measurement group_id="O4" value="-0.119" spread="0.0169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=149, 142, 147, 155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.0145"/>
                    <measurement group_id="O2" value="-0.076" spread="0.0148"/>
                    <measurement group_id="O3" value="-0.107" spread="0.0146"/>
                    <measurement group_id="O4" value="-0.102" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-peptide Levels</title>
        <description>C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-peptide Levels</title>
          <description>C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline C-peptide as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=142, 141, 141, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.0740"/>
                    <measurement group_id="O2" value="-0.551" spread="0.0741"/>
                    <measurement group_id="O3" value="-0.593" spread="0.0741"/>
                    <measurement group_id="O4" value="-0.452" spread="0.0729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=158, 150, 153, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.0701"/>
                    <measurement group_id="O2" value="-0.606" spread="0.0718"/>
                    <measurement group_id="O3" value="-0.620" spread="0.0711"/>
                    <measurement group_id="O4" value="-0.547" spread="0.0704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=158, 150, 154, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" spread="0.0676"/>
                    <measurement group_id="O2" value="-0.612" spread="0.0693"/>
                    <measurement group_id="O3" value="-0.534" spread="0.0684"/>
                    <measurement group_id="O4" value="-0.536" spread="0.0680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=158, 150, 154, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" spread="0.0801"/>
                    <measurement group_id="O2" value="-0.604" spread="0.0822"/>
                    <measurement group_id="O3" value="-0.424" spread="0.0810"/>
                    <measurement group_id="O4" value="-0.353" spread="0.0805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=158, 150, 154, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.097" spread="0.0783"/>
                    <measurement group_id="O2" value="-0.623" spread="0.0803"/>
                    <measurement group_id="O3" value="-0.556" spread="0.0792"/>
                    <measurement group_id="O4" value="-0.374" spread="0.0787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=158, 150, 154, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.068" spread="0.0752"/>
                    <measurement group_id="O2" value="-0.577" spread="0.0771"/>
                    <measurement group_id="O3" value="-0.541" spread="0.0760"/>
                    <measurement group_id="O4" value="-0.444" spread="0.0756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance</title>
        <description>The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements:
HOMA IR = fasting plasma insulin (µIU/mL) * fasting plasma glucose (mmol/L) / 22.5
A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Calculated Homeostatic Model Assessment Insulin Resistance</title>
          <description>The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements:
HOMA IR = fasting plasma insulin (µIU/mL) * fasting plasma glucose (mmol/L) / 22.5
A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA IR as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>insulin resistance</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 137, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.814" spread="0.5309"/>
                    <measurement group_id="O2" value="-3.479" spread="0.5458"/>
                    <measurement group_id="O3" value="-2.905" spread="0.5348"/>
                    <measurement group_id="O4" value="-3.877" spread="0.5236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=145, 134, 144, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.353" spread="0.3566"/>
                    <measurement group_id="O2" value="-3.350" spread="0.3717"/>
                    <measurement group_id="O3" value="-3.646" spread="0.3579"/>
                    <measurement group_id="O4" value="-3.508" spread="0.3532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostatic Model Assessment Beta Cell Function</title>
        <description>The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population.
HOMA %B = 20 * insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5
The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostatic Model Assessment Beta Cell Function</title>
          <description>The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population.
HOMA %B = 20 * insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5
The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HOMA beta cell function as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>percentage beta cell function</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n= 139, 132, 137, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.133" spread="4.2787"/>
                    <measurement group_id="O2" value="17.328" spread="4.3868"/>
                    <measurement group_id="O3" value="30.266" spread="4.3006"/>
                    <measurement group_id="O4" value="22.134" spread="4.2098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=145, 134, 144, 148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.472" spread="8.5306"/>
                    <measurement group_id="O2" value="17.500" spread="8.8718"/>
                    <measurement group_id="O3" value="39.153" spread="8.5455"/>
                    <measurement group_id="O4" value="24.887" spread="8.4285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight</title>
        <description>Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.</description>
        <time_frame>Baseline and Weeks 8, 12, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight</title>
          <description>Change from Baseline in body weight was assessed at Weeks 8, 12, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline weight as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=155, 146, 152, 151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.184"/>
                    <measurement group_id="O2" value="0.58" spread="0.189"/>
                    <measurement group_id="O3" value="0.82" spread="0.185"/>
                    <measurement group_id="O4" value="0.70" spread="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=159, 147, 155, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.227"/>
                    <measurement group_id="O2" value="0.96" spread="0.236"/>
                    <measurement group_id="O3" value="1.35" spread="0.230"/>
                    <measurement group_id="O4" value="1.22" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=159, 147, 155, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.265"/>
                    <measurement group_id="O2" value="1.56" spread="0.275"/>
                    <measurement group_id="O3" value="2.36" spread="0.268"/>
                    <measurement group_id="O4" value="1.86" spread="0.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=159, 147, 155, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.291"/>
                    <measurement group_id="O2" value="2.19" spread="0.302"/>
                    <measurement group_id="O3" value="3.14" spread="0.295"/>
                    <measurement group_id="O4" value="2.51" spread="0.296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol Level</title>
        <description>Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol Level</title>
          <description>Change from Baseline in total cholesterol level was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline total cholesterol as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=146, 144, 142, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="2.22"/>
                    <measurement group_id="O2" value="0.9" spread="2.23"/>
                    <measurement group_id="O3" value="-0.4" spread="2.25"/>
                    <measurement group_id="O4" value="-5.3" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=160, 151, 154, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="2.30"/>
                    <measurement group_id="O2" value="7.2" spread="2.37"/>
                    <measurement group_id="O3" value="-0.3" spread="2.34"/>
                    <measurement group_id="O4" value="-1.2" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="2.43"/>
                    <measurement group_id="O2" value="4.9" spread="2.51"/>
                    <measurement group_id="O3" value="-0.6" spread="2.47"/>
                    <measurement group_id="O4" value="4.4" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="2.42"/>
                    <measurement group_id="O2" value="4.6" spread="2.49"/>
                    <measurement group_id="O3" value="3.8" spread="2.46"/>
                    <measurement group_id="O4" value="4.7" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.67"/>
                    <measurement group_id="O2" value="4.5" spread="2.75"/>
                    <measurement group_id="O3" value="-0.3" spread="2.71"/>
                    <measurement group_id="O4" value="-0.6" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.61"/>
                    <measurement group_id="O2" value="6.5" spread="2.68"/>
                    <measurement group_id="O3" value="3.7" spread="2.65"/>
                    <measurement group_id="O4" value="4.0" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low-Density Lipoprotein Cholesterol</title>
        <description>Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low-Density Lipoprotein Cholesterol</title>
          <description>Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL cholesterol as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=137, 130, 135, 142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.88"/>
                    <measurement group_id="O2" value="2.8" spread="1.93"/>
                    <measurement group_id="O3" value="2.2" spread="1.89"/>
                    <measurement group_id="O4" value="-2.8" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=152, 139, 147, 153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.96"/>
                    <measurement group_id="O2" value="7.6" spread="2.05"/>
                    <measurement group_id="O3" value="2.6" spread="1.99"/>
                    <measurement group_id="O4" value="1.3" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=154, 140, 148, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.02"/>
                    <measurement group_id="O2" value="5.8" spread="2.12"/>
                    <measurement group_id="O3" value="1.4" spread="2.06"/>
                    <measurement group_id="O4" value="3.9" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=154, 140, 148, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.22"/>
                    <measurement group_id="O2" value="6.6" spread="2.33"/>
                    <measurement group_id="O3" value="5.3" spread="2.27"/>
                    <measurement group_id="O4" value="4.6" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=154, 140, 148, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.27"/>
                    <measurement group_id="O2" value="7.4" spread="2.38"/>
                    <measurement group_id="O3" value="2.1" spread="2.32"/>
                    <measurement group_id="O4" value="0.5" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=154, 140, 148, 154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.22"/>
                    <measurement group_id="O2" value="8.1" spread="2.33"/>
                    <measurement group_id="O3" value="4.6" spread="2.27"/>
                    <measurement group_id="O4" value="3.8" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-Density Lipoprotein Cholesterol</title>
        <description>Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-Density Lipoprotein Cholesterol</title>
          <description>Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL cholesterol as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=146, 144, 142, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.54"/>
                    <measurement group_id="O2" value="3.0" spread="0.54"/>
                    <measurement group_id="O3" value="3.8" spread="0.55"/>
                    <measurement group_id="O4" value="3.0" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=160, 151, 154, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.56"/>
                    <measurement group_id="O2" value="4.7" spread="0.58"/>
                    <measurement group_id="O3" value="5.0" spread="0.57"/>
                    <measurement group_id="O4" value="4.8" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.64"/>
                    <measurement group_id="O2" value="6.0" spread="0.66"/>
                    <measurement group_id="O3" value="6.4" spread="0.65"/>
                    <measurement group_id="O4" value="6.5" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.57"/>
                    <measurement group_id="O2" value="5.2" spread="0.58"/>
                    <measurement group_id="O3" value="6.0" spread="0.58"/>
                    <measurement group_id="O4" value="5.9" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.59"/>
                    <measurement group_id="O2" value="4.7" spread="0.60"/>
                    <measurement group_id="O3" value="5.6" spread="0.60"/>
                    <measurement group_id="O4" value="5.6" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.64"/>
                    <measurement group_id="O2" value="5.7" spread="0.66"/>
                    <measurement group_id="O3" value="6.2" spread="0.65"/>
                    <measurement group_id="O4" value="6.2" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglyceride Levels</title>
        <description>Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglyceride Levels</title>
          <description>Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline triglycerides as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=146, 144, 142, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.2" spread="8.60"/>
                    <measurement group_id="O2" value="-43.2" spread="8.63"/>
                    <measurement group_id="O3" value="-51.7" spread="8.70"/>
                    <measurement group_id="O4" value="-32.1" spread="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=160, 151, 154, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="6.51"/>
                    <measurement group_id="O2" value="-38.2" spread="6.69"/>
                    <measurement group_id="O3" value="-61.6" spread="6.63"/>
                    <measurement group_id="O4" value="-51.9" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.4" spread="6.90"/>
                    <measurement group_id="O2" value="-47.9" spread="7.09"/>
                    <measurement group_id="O3" value="-64.3" spread="7.00"/>
                    <measurement group_id="O4" value="-45.4" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.5" spread="5.74"/>
                    <measurement group_id="O2" value="-48.3" spread="5.90"/>
                    <measurement group_id="O3" value="-54.6" spread="5.82"/>
                    <measurement group_id="O4" value="-43.9" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.9" spread="7.35"/>
                    <measurement group_id="O2" value="-46.6" spread="7.56"/>
                    <measurement group_id="O3" value="-59.3" spread="7.46"/>
                    <measurement group_id="O4" value="-46.5" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=160, 151, 155, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="6.83"/>
                    <measurement group_id="O2" value="-46.6" spread="7.02"/>
                    <measurement group_id="O3" value="-56.2" spread="6.92"/>
                    <measurement group_id="O4" value="-43.1" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Free Fatty Acids</title>
        <description>Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Free Fatty Acids</title>
          <description>Change from Baseline in free fatty acids (FFA) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline free fatty acid as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=148, 136, 140, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0404" spread="0.01643"/>
                    <measurement group_id="O2" value="-0.0990" spread="0.01716"/>
                    <measurement group_id="O3" value="-0.1061" spread="0.01690"/>
                    <measurement group_id="O4" value="-0.0805" spread="0.01650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=154, 136, 147, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0429" spread="0.01624"/>
                    <measurement group_id="O2" value="-0.0680" spread="0.01729"/>
                    <measurement group_id="O3" value="-0.0881" spread="0.01662"/>
                    <measurement group_id="O4" value="-0.1013" spread="0.01647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasminogen Activator Inhibitor-1</title>
        <description>Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasminogen Activator Inhibitor-1</title>
          <description>Change from Baseline in plasminogen activator inhibitor-1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline plasminogen activator inhibitor-1 as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>ng/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=136, 127, 131, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="2.815"/>
                    <measurement group_id="O2" value="-4.23" spread="2.909"/>
                    <measurement group_id="O3" value="-9.63" spread="2.870"/>
                    <measurement group_id="O4" value="-11.87" spread="2.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=145, 129, 142, 137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="3.151"/>
                    <measurement group_id="O2" value="-5.45" spread="3.341"/>
                    <measurement group_id="O3" value="-7.14" spread="3.189"/>
                    <measurement group_id="O4" value="-8.38" spread="3.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High-sensitivity C-Reactive Protein</title>
        <description>Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High-sensitivity C-Reactive Protein</title>
          <description>Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline hsCRP as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=147, 134, 138, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4497" spread="0.41497"/>
                    <measurement group_id="O2" value="-1.7446" spread="0.43493"/>
                    <measurement group_id="O3" value="-1.5346" spread="0.42831"/>
                    <measurement group_id="O4" value="-2.2771" spread="0.41646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=153, 135, 144, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1851" spread="0.42623"/>
                    <measurement group_id="O2" value="-1.0391" spread="0.45388"/>
                    <measurement group_id="O3" value="-1.9763" spread="0.43925"/>
                    <measurement group_id="O4" value="-1.9796" spread="0.43182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin</title>
        <description>Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin</title>
          <description>Change from Baseline in adiponectin was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline adiponectin as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>μg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=148, 137, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.560"/>
                    <measurement group_id="O2" value="6.35" spread="0.582"/>
                    <measurement group_id="O3" value="8.10" spread="0.575"/>
                    <measurement group_id="O4" value="7.50" spread="0.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=154, 137, 147, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.570"/>
                    <measurement group_id="O2" value="6.90" spread="0.605"/>
                    <measurement group_id="O3" value="6.85" spread="0.586"/>
                    <measurement group_id="O4" value="7.16" spread="0.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A1</title>
        <description>Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A1</title>
          <description>Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and Baseline apolipoprotein A1 as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=140, 138, 137, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="1.57"/>
                    <measurement group_id="O2" value="2.3" spread="1.58"/>
                    <measurement group_id="O3" value="1.0" spread="1.59"/>
                    <measurement group_id="O4" value="1.7" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=149, 139, 146, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" spread="1.59"/>
                    <measurement group_id="O2" value="1.2" spread="1.64"/>
                    <measurement group_id="O3" value="0.8" spread="1.60"/>
                    <measurement group_id="O4" value="1.6" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein A2</title>
        <description>Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein A2</title>
          <description>Change from Baseline in apolipoprotein A2 was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein A2 as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=140, 138, 137, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.41"/>
                    <measurement group_id="O2" value="3.4" spread="0.41"/>
                    <measurement group_id="O3" value="2.8" spread="0.41"/>
                    <measurement group_id="O4" value="3.2" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=149, 139, 146, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.41"/>
                    <measurement group_id="O2" value="2.9" spread="0.43"/>
                    <measurement group_id="O3" value="2.5" spread="0.42"/>
                    <measurement group_id="O4" value="2.6" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein B</title>
        <description>Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein B</title>
          <description>Change from Baseline in apolipoprotein B was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein B as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=140, 138, 137, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="1.76"/>
                    <measurement group_id="O2" value="-5.0" spread="1.78"/>
                    <measurement group_id="O3" value="-9.8" spread="1.78"/>
                    <measurement group_id="O4" value="-5.9" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=149, 139, 146, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.84"/>
                    <measurement group_id="O2" value="-3.7" spread="1.91"/>
                    <measurement group_id="O3" value="-7.9" spread="1.86"/>
                    <measurement group_id="O4" value="-6.4" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Apolipoprotein C-III</title>
        <description>Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Apolipoprotein C-III</title>
          <description>Change from Baseline in apolipoprotein C-III was assessed at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline apolipoprotein C-III as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=140, 138, 138, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.30"/>
                    <measurement group_id="O2" value="-0.3" spread="0.30"/>
                    <measurement group_id="O3" value="-0.8" spread="0.30"/>
                    <measurement group_id="O4" value="-0.3" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=149, 139, 147, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.28"/>
                    <measurement group_id="O2" value="-0.2" spread="0.29"/>
                    <measurement group_id="O3" value="-0.3" spread="0.28"/>
                    <measurement group_id="O4" value="-0.4" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides</title>
        <description>Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides</title>
          <description>Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline NMR total triglycerides as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="6.36"/>
                    <measurement group_id="O2" value="-25.0" spread="6.52"/>
                    <measurement group_id="O3" value="-39.7" spread="6.52"/>
                    <measurement group_id="O4" value="-23.7" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="5.82"/>
                    <measurement group_id="O2" value="-20.2" spread="6.11"/>
                    <measurement group_id="O3" value="-28.8" spread="5.94"/>
                    <measurement group_id="O4" value="-22.6" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles</title>
        <description>The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles</title>
          <description>The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron particles as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.59" spread="2.600"/>
                    <measurement group_id="O2" value="0.70" spread="2.663"/>
                    <measurement group_id="O3" value="-9.63" spread="2.664"/>
                    <measurement group_id="O4" value="-2.67" spread="2.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.97" spread="2.831"/>
                    <measurement group_id="O2" value="4.94" spread="2.976"/>
                    <measurement group_id="O3" value="-0.73" spread="2.888"/>
                    <measurement group_id="O4" value="-1.17" spread="2.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.511"/>
                    <measurement group_id="O2" value="-1.83" spread="0.525"/>
                    <measurement group_id="O3" value="-2.63" spread="0.525"/>
                    <measurement group_id="O4" value="-2.06" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.480"/>
                    <measurement group_id="O2" value="-1.96" spread="0.505"/>
                    <measurement group_id="O3" value="-2.37" spread="0.490"/>
                    <measurement group_id="O4" value="-2.11" spread="0.480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VLDL / Chylomicron Triglycerides</title>
        <description>The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VLDL / Chylomicron Triglycerides</title>
          <description>The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL/chylomicron triglycerides as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="6.34"/>
                    <measurement group_id="O2" value="-25.6" spread="6.50"/>
                    <measurement group_id="O3" value="-39.5" spread="6.50"/>
                    <measurement group_id="O4" value="-24.2" spread="6.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="5.79"/>
                    <measurement group_id="O2" value="-22.0" spread="6.08"/>
                    <measurement group_id="O3" value="-29.7" spread="5.90"/>
                    <measurement group_id="O4" value="-23.3" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in VLDL Particles</title>
        <description>The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in VLDL Particles</title>
          <description>The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline VLDL particles as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medium Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.20" spread="1.639"/>
                    <measurement group_id="O2" value="-2.30" spread="1.678"/>
                    <measurement group_id="O3" value="-8.52" spread="1.679"/>
                    <measurement group_id="O4" value="-4.69" spread="1.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="1.784"/>
                    <measurement group_id="O2" value="-0.39" spread="1.874"/>
                    <measurement group_id="O3" value="-3.76" spread="1.819"/>
                    <measurement group_id="O4" value="-3.58" spread="1.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="1.617"/>
                    <measurement group_id="O2" value="4.77" spread="1.662"/>
                    <measurement group_id="O3" value="1.18" spread="1.660"/>
                    <measurement group_id="O4" value="3.71" spread="1.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.11" spread="1.710"/>
                    <measurement group_id="O2" value="7.16" spread="1.802"/>
                    <measurement group_id="O3" value="5.22" spread="1.746"/>
                    <measurement group_id="O4" value="4.36" spread="1.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean VLDL Particle Size</title>
        <description>Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean VLDL Particle Size</title>
          <description>Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean VLDL particle size as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.668"/>
                    <measurement group_id="O2" value="-3.97" spread="0.688"/>
                    <measurement group_id="O3" value="-2.92" spread="0.687"/>
                    <measurement group_id="O4" value="-2.85" spread="0.665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.607"/>
                    <measurement group_id="O2" value="-3.71" spread="0.640"/>
                    <measurement group_id="O3" value="-4.21" spread="0.620"/>
                    <measurement group_id="O4" value="-2.80" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles</title>
        <description>The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles</title>
          <description>The change from Baseline in levels of IDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline IDL particles as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="3.63"/>
                    <measurement group_id="O2" value="-1.0" spread="3.72"/>
                    <measurement group_id="O3" value="-2.9" spread="3.73"/>
                    <measurement group_id="O4" value="-4.0" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.68"/>
                    <measurement group_id="O2" value="2.1" spread="3.86"/>
                    <measurement group_id="O3" value="-1.0" spread="3.75"/>
                    <measurement group_id="O4" value="-5.8" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Low Density Lipoprotein (LDL) Particles</title>
        <description>The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low Density Lipoprotein (LDL) Particles</title>
          <description>The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline LDL particles as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="28.57"/>
                    <measurement group_id="O2" value="-104.1" spread="29.34"/>
                    <measurement group_id="O3" value="-207.0" spread="29.33"/>
                    <measurement group_id="O4" value="-181.8" spread="28.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.9" spread="30.67"/>
                    <measurement group_id="O2" value="-75.6" spread="32.29"/>
                    <measurement group_id="O3" value="-169.9" spread="31.31"/>
                    <measurement group_id="O4" value="-177.1" spread="30.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="15.16"/>
                    <measurement group_id="O2" value="98.8" spread="15.52"/>
                    <measurement group_id="O3" value="129.4" spread="15.54"/>
                    <measurement group_id="O4" value="142.1" spread="15.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="15.32"/>
                    <measurement group_id="O2" value="120.4" spread="16.10"/>
                    <measurement group_id="O3" value="146.6" spread="15.63"/>
                    <measurement group_id="O4" value="155.5" spread="15.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium-Small - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="6.25"/>
                    <measurement group_id="O2" value="-41.4" spread="6.41"/>
                    <measurement group_id="O3" value="-65.8" spread="6.41"/>
                    <measurement group_id="O4" value="-65.8" spread="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium-Small - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="6.42"/>
                    <measurement group_id="O2" value="-40.1" spread="6.75"/>
                    <measurement group_id="O3" value="-63.0" spread="6.55"/>
                    <measurement group_id="O4" value="-66.6" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Small - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.8" spread="31.91"/>
                    <measurement group_id="O2" value="-200.3" spread="32.71"/>
                    <measurement group_id="O3" value="-331.2" spread="32.73"/>
                    <measurement group_id="O4" value="-320.0" spread="31.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Small - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" spread="33.34"/>
                    <measurement group_id="O2" value="-195.8" spread="35.04"/>
                    <measurement group_id="O3" value="-313.8" spread="34.01"/>
                    <measurement group_id="O4" value="-327.4" spread="33.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Small - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="26.22"/>
                    <measurement group_id="O2" value="-159.2" spread="26.88"/>
                    <measurement group_id="O3" value="-265.7" spread="26.90"/>
                    <measurement group_id="O4" value="-254.2" spread="26.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Small - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.1" spread="27.44"/>
                    <measurement group_id="O2" value="-156.0" spread="28.83"/>
                    <measurement group_id="O3" value="-250.9" spread="27.98"/>
                    <measurement group_id="O4" value="-260.8" spread="27.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean LDL Particle Size</title>
        <description>Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean LDL Particle Size</title>
          <description>Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean LDL particle size as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.051"/>
                    <measurement group_id="O2" value="0.44" spread="0.053"/>
                    <measurement group_id="O3" value="0.63" spread="0.053"/>
                    <measurement group_id="O4" value="0.58" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.052"/>
                    <measurement group_id="O2" value="0.44" spread="0.054"/>
                    <measurement group_id="O3" value="0.65" spread="0.053"/>
                    <measurement group_id="O4" value="0.61" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Density Lipoprotein (HDL) Particles</title>
        <description>The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein (HDL) Particles</title>
          <description>The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12 and 26.
Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline HDL particles as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>µmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.350"/>
                    <measurement group_id="O2" value="0.92" spread="0.359"/>
                    <measurement group_id="O3" value="0.11" spread="0.359"/>
                    <measurement group_id="O4" value="0.54" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.359"/>
                    <measurement group_id="O2" value="1.67" spread="0.377"/>
                    <measurement group_id="O3" value="1.01" spread="0.367"/>
                    <measurement group_id="O4" value="1.03" spread="0.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.195"/>
                    <measurement group_id="O2" value="0.99" spread="0.200"/>
                    <measurement group_id="O3" value="0.98" spread="0.200"/>
                    <measurement group_id="O4" value="1.31" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.197"/>
                    <measurement group_id="O2" value="1.14" spread="0.207"/>
                    <measurement group_id="O3" value="1.24" spread="0.201"/>
                    <measurement group_id="O4" value="1.31" spread="0.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.311"/>
                    <measurement group_id="O2" value="0.72" spread="0.319"/>
                    <measurement group_id="O3" value="1.60" spread="0.320"/>
                    <measurement group_id="O4" value="1.61" spread="0.308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medium Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.313"/>
                    <measurement group_id="O2" value="0.95" spread="0.329"/>
                    <measurement group_id="O3" value="1.19" spread="0.320"/>
                    <measurement group_id="O4" value="1.30" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Particles - Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.412"/>
                    <measurement group_id="O2" value="-0.68" spread="0.423"/>
                    <measurement group_id="O3" value="-2.65" spread="0.423"/>
                    <measurement group_id="O4" value="-2.42" spread="0.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small Particles - Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="0.412"/>
                    <measurement group_id="O2" value="-0.28" spread="0.433"/>
                    <measurement group_id="O3" value="-1.58" spread="0.421"/>
                    <measurement group_id="O4" value="-1.63" spread="0.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean HDL Particle Size</title>
        <description>Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.</description>
        <time_frame>Baseline and Weeks 12 and 26.</time_frame>
        <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
        <group_list>
          <group group_id="O1">
            <title>Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone 30 mg</title>
            <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean HDL Particle Size</title>
          <description>Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12 and 26. Least squares means are from an ANCOVA model with treatment and geographic region as class variables and baseline mean HDL particle size as a covariate.</description>
          <population>The full analysis set where Baseline and at least 1 postbaseline value were available. Last observation carried forward (LOCF) imputation was utilized.</population>
          <units>nm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (n=139, 132, 132, 141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.024"/>
                    <measurement group_id="O2" value="0.09" spread="0.025"/>
                    <measurement group_id="O3" value="0.17" spread="0.025"/>
                    <measurement group_id="O4" value="0.15" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=147, 133, 141, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.024"/>
                    <measurement group_id="O2" value="0.08" spread="0.025"/>
                    <measurement group_id="O3" value="0.15" spread="0.024"/>
                    <measurement group_id="O4" value="0.14" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of informed consent until the end of the study, and from spontaneous reporting for 30 days after the end of treatment.</time_frame>
      <desc>At each study visit, the investigator assessed whether any events had occurred. Patients could report events at any other time during the study. All events, whether reported by the patient or observed by the investigator, were documented, whether or not the investigator concluded the event to be related to the drug treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alogliptin 25 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Pioglitazone 30 mg</title>
          <description>Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Alogliptin 25 mg + Pioglitazone 30 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Alogliptin 12.5 mg + Pioglitazone 30 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="163"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be published prior to publication of a multi-center report submitted for publication within 18 months after conclusion or termination of a study at all study sites. Results publications will be submitted to sponsor for review 60 days in advance of publication. Sponsor can require removal of confidential information unrelated to study results. Sponsor can embargo a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

